Record half-year revenue and EBITDA were achieved, driven by strong growth in both medical equipment/IT and radiopharmaceuticals, with significant new contracts and a robust backlog supporting a positive outlook for the second half. Recurring revenue is set to rise, and the company is well-positioned for further expansion.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.